SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Ratnam, M. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Ratnam, M. Related Collections Neoplasia Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 November 2000, Vol. 96, No. 10, pp. 3529-3536 NEOPLASIA Differentiation-independent retinoid induction of folate receptor type , a potential tumor target in myeloid leukemia Hui Wang, Xuan Zheng, Frederick G. Behm, and Manohar Ratnam From the Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, OH, and the Department of Immunopathology, St. Jude's Children's Research Hospital, Memphis, TN.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Folate receptor (FR) type  is expressed in the myelomonocytic lineage, predominantly during neutrophil maturation and in myeloid leukemias. FR- expression was elevated up to 20-fold by all-trans retinoic acid (ATRA) in KG-1 myeloid leukemia cells in a dose-dependent and reversible manner in the absence of terminal differentiation or cell growth inhibition. ATRA also increased FR- expression in vitro in myeloid leukemia cells from patient marrow. FR- was not up-regulated in KG-1 cells treated with phorbol ester, dexamethasone, 1,25-dihydroxy vitamin D3, or transforming growth factor . ATRA did not induce FR- expression in receptor negative cells of diverse origin. The ATRA-induced increase in FR- expression in KG-1 cells occurred at the level of messenger RNA synthesis, and in 293 cells containing a stably integrated FR- promoter-luciferase reporter construct, ATRA induced expression of the reporter. From experiments using retinoid agonists and antagonists and from cotransfection studies using the FR- promoter and expression plasmids for the nuclear receptors retinoic acid receptor (RAR), RAR, or RAR, it appears that the retinoid effect on FR- expression could be mediated by ligand binding to RARs , , or , but not to retinoid X receptors. Furthermore, there was apparent cross-talk between RAR and RAR selective agonists or antagonists, suggesting a common downstream target for RAR isoforms in inducing FR- expression. Thus, blocks in the RAR-specific pathway of retinoid-induced differentiation may be bypassed during retinoid induction of FR- expression. The results suggest that to facilitate FR-targeted therapies, retinoids may be used to modulate FR- expression in myeloid leukemia cells refractory to retinoid differentiation therapy. (Blood. 2000;96:3529-3536) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References The human folate receptor (FR) is a single polypeptide glycoprotein encoded by a family of 3 genes.1-4 FR- and FR- are attached to the cell surface by a glycosyl-phosphatidylinositol (GPI) membrane anchor,5 whereas FR- is constitutively secreted.3 The membrane-anchored proteins mediate internalization of receptor-bound folate compounds and folate conjugates.6,7 The FR isoforms exhibit narrow tissue and tumor specificities. FR- is expressed in certain normal epithelial cells and is vastly elevated in various carcinomas, particularly those of gynecological tissues.8-10 In recent preclinical and clinical studies, primarily of ovarian cancer, FR- has shown considerable promise as a potential means of delivering a wide variety of novel folate-mediated and non-folate-mediated therapeutic agents to tumor cells and as a tumor and serum marker.11 FR- is highly expressed in placentas,2 mature neutrophils,12 and activated monocytes and macrophages,13 and in more than half of all myeloid leukemias12,14,15 (also unpublished data, 2000) and is virtually absent in other tissues. In normal hematopoiesis, FR- is expressed in the myelomonocytic lineage in a subpopulation of CD34+ cells, and its expression is further increased about 5-fold during neutrophil maturation.11,16 In normal hematopoietic cells, FR- does not bind folic acid with a high affinity even though its messenger RNA (mRNA) sequence is unaltered16 (also unpublished data, 2000). The function of FR- in normal hematopoietic cells is unclear since deletion of a gene presumably corresponding to this receptor isoform did not produce an altered phenotype in mice.17 Nevertheless, the restricted expression of FR- in later stages of normal myelopoiesis renders this FR isoform a potential target for novel FR-mediated therapies in myeloid leukemia. At present, the most effective treatment for myeloid leukemia is retinoid differentiation therapy, for which acute promyelocytic leukemia (APL) is the paradigm, since in various studies 72% to 95% of APL patients have shown complete remission owing to treatment with all-trans retinoic acid (ATRA).18 Other types of acute myeloid leukemia (AML), which constitute about 90% of AML cases, do not respond well to ATRA therapy. Furthermore, in APL, the initial favorable response to ATRA treatment is followed by a significant incidence of relapse, at which time the patients are refractory to ATRA differentiation therapy.18 In those cases, ATRA resistance has frequently been related to mutations that cause blocks in the pathway of retinoid-induced differentiation.19 We report here that in KG-1 myeloid leukemia cells and also in leukemic blasts from patients with non-APL AMLs, ATRA induces FR- expression and that this effect occurs in the absence of terminal differentiation or inhibition of cell proliferation. The cell type, inducing reagent, and nuclear receptor specificities of this effect support the feasibility of developing more effective therapies for myeloid leukemia by combining FR- targeting and retinoid treatment.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cells and reagents NB4 and KCL22 cells were kindly provided by Dr H. Philip Koeffler (University of California, Los Angeles). All of the other cell lines were purchased from American Type Culture Collection (Rockville, MD). Cells were cultured at 37°C in 5% CO2. The cell-culture media were supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 292 µg/mL L-glutamine (Gibco-BRL, Grand Island, NY). Caki-1, CCRF-CEM, Hela, KCL22, and NB4 cells were grown in folate-free RPMI-1640 medium (FFRPMI-1640) (JRH Bioscience, Lenexa, KS) with 10% fetal bovine serum (FBS) (Gibco-BRL). K562, L1210, JAR, SKOV3, and 293 cells were grown in RPMI-1640 medium with 10% FBS. For transient transfection experiments, 293 cells were grown in Eagle's Minimum Essential Medium (MEM) (Gibco-BRL). HL60, KG-1, and KG-1a cells were grown in FFRPMI-1640 medium with 20% FBS. MG-63 cells were grown in Dulbecco's Modified Eagle's Medium (D-MEM) (Gibco-BRL) with 10% FBS. ATRA, 9-cis retinoic acid (9-cis RA), dexamethasone, phorbol 12-myristate 13-acetate (PMA), and 1,25(OH)2 vitamin D3 (vit D3) were purchased from Sigma-Aldrich (St. Louis, MO). Transforming growth factor  (TGF-) was purchased from R&D Systems, Inc (Minneapolis, MN). We dissolved 9-cis RA, dexamethasone, and vit D3 in ethanol to achieve stock solutions of 5 mmol/L. Compounds LG101093, TTNPB, LG100364, and LG100629 were a kind gift from Dr Elizabeth Allegreto (Ligand Pharmaceuticals Inc, San Diego, CA). ATRA and all of the compounds in the LG series were dissolved in a mixture of 50% ethanol and 50% dimethyl sulfoxide (DMSO). Compounds CD2314, CD2503, CD2665, CD2781, CD336, and CD417 were kindly provided by Dr Uwe Reichert (Galderma Research and Development, Valbonne, France). These compounds were dissolved in DMSO to achieve stock solutions of 5 × 102 mol/L. All the stock solutions were stored in aliquots at 80°C. Treatment of cells with retinoid compounds or other differentiation reagents For suspension cultures, cells growing in log phase were seeded into 60-mm or 100-mm tissue-culture plates at a density of 2.5 × 105 cells per milliliter in 4 mL or 8 mL of media, respectively. For monolayer cultures, the cells were seeded at 10% to 20% confluence into 6-well tissue-culture plates. After a 6-hour preculture, various retinoids or other differentiation reagents were added to the medium, either directly or after appropriate dilution, to obtain the final concentration of the reagent. After the desired period of incubation, KG-1 cells and other suspension cells were harvested by sedimenting at 400g for 10 minutes and suspending in phosphate-buffered saline (PBS) (10 mmol/L sodium phosphate, pH 7.5, per 150 mmol/L NaCl) at 4°C. This washing procedure was repeated once before the cells were used for immunostaining, cell lysate preparation, or other procedures described below. The monolayer cells were washed in the culture plates twice with PBS and subjected to either [3H] folic acid binding assay or cell lysate preparation. Treatment of leukemic blasts with ATRA Leukemic blasts from patient bone marrow aspirates, separated by Ficoll density gradient centrifugation, were received frozen from the Pediatric Oncology Group tissue bank (St. Jude's Children's Hospital, Memphis, TN). The cells were rapidly thawed under hot running water and immediately resuspended at 37°C in RPMI-1640 containing 30% FBS. The cells were sedimented at 400g for 10 minutes and seeded at a density of 2.5 × 105 cell/mL in RPMI-1640 medium containing 20% FBS with the inclusion of interleukin 3 (IL-3) (20 ng/mL), human stem cell factor (cKit ligand) (20 ng/mL), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng/mL) (R&D Systems, Inc). The cells were treated with ATRA as described above. Folate binding assay Cells were washed with ice-cold acid buffer (10 mmol/L sodium acetate, pH 3.5, containing 150 mmol/L NaCl) and cold PBS sequentially. The cells were then incubated with 1 mL PBS containing a mixture of 5 pmol of [3H] folic acid (20.2 Ci/mmol) (Moravek Biochemicals, Brea, CA) and 25 pmol of unlabeled folic acid at 4°C for 30 minutes. After the incubation, the cells were washed twice with cold PBS. The acid buffer (1 mL) was used to extract bound [3H] folic acid, and the radioactivity was measured by liquid scintillation counting. Preparation of cell lysate and Western blot analysis Cells (1 × 106) were lysed at 37°C for 45 minutes in 30 µL of PBS containing 1% Triton X-100 and 1 mmol/L phenylmethanesulfonyl fluoride.20 After sedimenting the insoluble material by centrifugation at 10 000g for 10 minutes, we mixed 25 µL of the supernatant (cell lysate) with an equal volume of 2 × sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (62.5 mmol/L Tris-HCl, pH 6.8, containing 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.00125% bromophenol blue). The samples were electrophoresed on 12% SDS-PAGE gels and transferred to nitrocellulose filters. The blots were probed with affinity-purified rabbit antihuman FR- antibody followed by alkaline phosphatase-conjugated goat antirabbit immunoglobulin G (IgG) (Promega, Madison, WI) as previously described.2,20 Immunostaining for flow cytometry analysis Cells were washed and resuspended in PBS at a density of 1 × 107 cells per milliliter. Aliquots (100 µL) of the cell suspension were incubated with either rabbit anti-FR- antibody or normal rabbit serum (1:20 dilution in PBS) on ice for 60 minutes with intermittent gentle agitation. The cells were washed twice with PBS and incubated with fluorescein isothiocyonate (FITC)-conjugated goat antirabbit IgG (1:500 dilution) in 500 µL PBS on ice for 30 minutes with intermittent gentle agitation (Cappel, Durham, NC). After 2 more washes with PBS, the cells were fixed in 300 µL of 1% paraformaldehyde and stored at 4°C. The samples were examined in a flow cytometer within 24 hours. MTT assay MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was purchased from Sigma (St. Louis, MO), and MTT cell proliferation assay was carried out following the supplier's protocol. Briefly, 90 µL aliquots of KG-1 or HL60 cells were added to each well of a 96-well plate followed by the addition of 10 µL of MTT stock solution (5 mg/mL) and incubation at 37°C for 3 to 4 hours. The reaction was stopped by adding 100 µL of 0.1 N HCl in isopropanol. The optical density was measured at 570 nm with background subtraction at 630 to 690 nm. Nitroblue tetrazolium reduction assay and -naphthyl acetate esterase staining The cells were harvested and suspended at a density of 1 × 106/mL. The cell suspensions (100 µL) were treated for the measurement of nitroblue tetrazolium (NBT) reduction activity as described.21 We spread 20 µL of the cell suspensions evenly onto microscope slides (Labcraft, distributed by Curtin Matheson Scientific, Inc, Houston, TX). The slides were stained by means of the -naphthyl acetate esterase (NAE) kit (Sigma) following the manufacturer's protocol. Treatment with phosphatidylinositol-specific phospholipase C Cells (1 × 106) were incubated in 500 µL of phosphatidylinositol-specific phospholipase C (PI-PLC) buffer (25 mmol/L Tris-HCl, pH 7.5, containing 250 mmol/L sucrose, 10 mmol/L glucose, and 1% bovine serum albumin) at 37°C for 1 hour in either the presence or the absence of 0.15 U of PI-PLC (Boehringer Mannheim Corp, Indianapolis, IN) with mild agitation. Cells were then washed twice with PBS, and cell lysates were prepared for Western blot analysis as described above. Alternatively, crude membranes were prepared from the PI-PLC-treated cells as described previously.20 Isolation of total RNA and Northern blot analysis Total RNA was isolated with the use of Trizol reagent (Gibco-BRL) following the protocol provided by the vendor. Total RNA (30 µg) from each sample was analyzed by Northern blot as described previously.9 The blot was hybridized separately with [-32P] deoxyadenosine triphosphate (3000Ci/mmol, DuPont-New England Nuclear, Boston, MA) labeled complementary DNA (cDNA) fragments of FR- (nucleotides 591 to 933), FR- (nucleotides 558 to 900), or -actin. Nuclear run-on assay This procedure is a modification of the one described by Garber et al.22 Briefly, cells (5 × 107) were lysed in 5 mL of lysis buffer A (15 mmol/L Hepes, 60 mmol/L KCl, 15 mmol/L NaCl, 0.15 mmol/L spermin, 0.5 mmol/L spermidine, 0.5 mmol/L egtazic acid, 2 mmol/L EDTA, 0.3 mol/L sucrose, and 14 mmol/L -mercaptoethanol) containing 0.1% nonidet P-40. The nuclei were separated by centrifugation and finally resuspended gently in nuclear storage buffer (50 mmol/L Tris, pH 8.3, containing 40% glycerol, 5 mmol/L MgCl2, and 0.1 mmol/L EDTA), snap-frozen on dry ice and stored at 80°C up to 4 weeks. For each reaction, 107 nuclei were thawed on ice and resuspended with 300 µL reaction buffer (50 mmol/L Tris, pH 8.0, containing 150 mmol/L KCl, 5 mmol/L MgCl2, 0.5 mmol/L MnCl2, 2 mmol/L dithiothreitol, 0.1 mmol/L EDTA, 10% glycerol), and 60 U RNase inhibitor from Roche Diagnostic Corp (Indianapolis, IN). The reaction was initiated by the addition of ribonucleotides to a final concentration of 0.5 mmol/L adenosine triphosphate, 0.5 mmol/L guanosine 5'-triphosphate, 0.5 mmol/L cytidine 5'-triphosphate, and 100 µCi -32P] uridine triphosphate (800 Ci/mmol, DuPont-New England Nuclear). The reaction was first incubated in a water bath at 30°C followed by digestion with 100 U DNase I (Roche Diagnostics Corp) and 33 µg of proteinase K in 33 µL of 10 × second incubation buffer (100 mmol/L Tris-HCl, pH 7.5, containing 5% SDS, 50 mmol/L EDTA) at 37°C or 42°C, respectively. Each incubation step lasted for 30 minutes. The newly transcribed RNA was extracted with phenol-chloroform, precipitated with sodium acetate and ethanol, and purified on micro bio-spin columns P-30 Tris (Bio-Rad Laboratories, Hercules, CA). The purified RNA probes (1 × 106 to 3 × 106 cpm) were hybridized to FR- or -actin cDNA, which was immobilized on a nitrocellulose membrane, in 500 µL hybridization buffer at 45°C for 48 hours. Then the membrane was washed with 2 × SSPE at 45°C and sequentially washed with the same buffer containing either RNase A (Roche Diagnostics Corp) or proteinase K at 37°C. The membrane was then exposed to x-ray film. DNA constructs For FR- promoter-luciferase constructs, the FR- genomic DNA fragment 478nt to +64nt containing the transcription start-site at nucleotide +1 was inserted into the pGL3 basic vector (Promega) in the polylinker immediately upstream of the luciferase reporter. The retinoid acid receptor (RAR), RAR, and RAR cDNA constructs were kindly provided by Dr Pierre Chambon (Institute de Genetique et de Biologie Moleculaire et Cellulaire, Cude Strasbourg, France). Transient transfection and luciferase assay We transfected 293 cells, at 50% to 70% confluence in 6-well tissue-culture plates, with 1 µg each of the FR- promoter-luciferase construct, pSV--gal (Promega), and RAR, RAR, or RAR cDNA constructs using lipofectamine (Life Technologies, Inc, Gaithersburg, MD) according to the vendor's protocol. At 8 hours after transfection was initiated, the medium containing DNA complexes was removed and 2 mL of regular MEM medium containing ATRA (1 µmol/L) or the vehicle alone was added to each well. At 48 hours after transfection, the cells were harvested in the reporter lysis buffer provided in the luciferase assay system (Promega) and centrifuged at 14 000g for 2 minutes at room temperature. The supernatant was assayed for luciferase, -galactosidase activity, and total protein concentration, as previously described.23 Stable transfection and isolation of transfectant clones We cotransfected 293 cells, at 60% confluence in a 100-mm plate, with 9 µg of the FR- promoter-luciferase construct and 3 µg of pcDNA1/Neo plasmid (Invitrogen, Carlsbad, CA) using lipofectamine. At 40 hours after transfection, the cells were transferred into MEM medium containing G418 (0.5 mg/mL) (Gibco-BRL). At 72 hours after transfection, the cells were split at different ratios (1:3 to 1:24) and cultured in 100-mm plates. After about 2 more weeks, individual colonies were picked and cultured.     Results Top Abstract Introduction Materials and methods Results Discussion References Specific and reversible up-regulation of FR- by ATRA in KG-1 cells KG-1 leukemia cells express FR-, which may be detected on the cell membrane by FR--specific antibodies (Figure 1). When the cells were grown in the presence of ATRA, there was a dramatic dose-dependent increase in FR- expression up to a concentration of 106 mol/L ATRA. The elevation in FR- could be demonstrated by an increase in the intensity of a protein of apparent molecular weight of approximately 36 000 on a Western blot (Figure 1A) probed with a rabbit antibody that is specific for FR- but that is not cross-reactive with FR-.12 Flow cytometric quantitation of the cell-surface-associated FR- showed an elevation of the receptor by approximately 20-fold in the presence of 106 mol/L ATRA (Figure 1B). The ATRA-induced increase in FR- occurred progressively over a 5-day period (Figure 1C). Withdrawal of ATRA at the end of a 5-day treatment resulted in an eventual decline in FR- (Figure 1D), indicating that the effect of ATRA on FR- expression is reversible. Treatment with 1 µmol/L ATRA for 5 days did not induce FR- expression or appreciably alter FR- expression in a variety of established cell lines, including myeloid leukemia cells, which either did not express FR or expressed only FR-. The cell lines tested and their FR expression pattern are indicated in Table 1. View larger version (24K): [in this window] [in a new window]   Figure 1. Dose response and time course of FR- induction by ATRA in KG-1 cells. (A) KG-1 cells were grown in the presence of the indicated concentrations of ATRA for 5 days. Crude membranes from the treated cells were probed by Western blot with the use of rabbit antihuman FR- antibody and alkaline phosphate (AP)-conjugated goat-antirabbit secondary antibody. (B) KG-1 cells were grown in the presence of ATRA as in panel A. On day 5, cells were washed with PBS and stained with anti-FR- antibody and FITC-conjugated secondary antibody and then examined by flow cytometry. (C) KG-1 cells were treated with 1 µmol/L ATRA for different periods, and cell surface FR- expression was quantitated by flow cytometry as in panel B. (D) KG-1 cells were grown in the absence (lane 1) or presence (lane 2) of 1 µmol/L ATRA for 5 days, and the cell lysates analyzed by Western blot. Alternatively, the ATRA-treated cells were washed and resuspended in medium without ATRA and grown for a further 7 days before Western blot analysis of the cell lysates (lane 3). The Western blot was probed with rabbit anti-FR- antibody and AP-conjugated secondary antibody.                                View this table: [in this window] [in a new window]   Table 1. Effect of all-trans retinoic acid on folate receptor expression in various cell lines PI-PLC sensitivity of ATRA-induced FR- in KG-1 cells When KG-1 cells were grown in the presence of ATRA to induce FR- expression and then treated with PI-PLC, there was a quantitative decrease in the FR- detected by Western blot in the cell lysate (results not shown). The ability of PI-PLC to release a protein from the cell surface is a diagnostic test for the presence of a GPI membrane anchor in proteins including FR-. This result further confirms the cell surface localization and identity of the ATRA-induced band on Western blots of cell lysates from KG-1 cells. Effect of ATRA and other differentiating agents on growth, differentiation, and FR- expression in KG-1 cells In contrast to the growth-inhibitory effect of ATRA on HL60 cells (approximately 50% growth inhibition in 5 days), the compound did not produce a significant inhibition in the growth of KG-1 cells (results not shown). Furthermore, in contrast to HL60 cells, ATRA did not cause differentiation of KG-1 cells along the granulocytic lineage as monitored by the NBT reduction assay (Table 2). Other differentiating agents, ie, phorbol ester and dexamethasone, also did not induce granulocytic differentiation in KG-1 cells (Table 2). On the other hand, phorbol ester, but not ATRA or dexamethasone, could induce KG-1 cells to differentiate along the monocytic lineage as determined by NAE staining (Table 2). In contrast to ATRA, however, a variety of differentiating agents (ie, PMA, dexamethasone, vit D3, and TGF-) had no apparent effect on FR- expression in KG-1 cells (Table 2).                                View this table: [in this window] [in a new window]   Table 2. Effects of various differentiation reagents on KG-1 cells Induction of FR- by ATRA in myeloid leukemia cells from patient marrow The effect of ATRA on FR- expression in leukemic cells in the bone marrow of AML patients was tested under cell-culture conditions in the presence of GM-CSF, IL-3, and cKit ligand to ensure cell viability. Leukemic blasts and mononuclear cells were obtained from the patient bone marrow aspirates by Ficoll density gradient centrifugation and cultured in suspension in either the presence or absence of 106 mol/L ATRA. The leukemic cells were derived from 2 patients with French-American-British (FAB)-M2 type (AML with maturation) leukemia and 2 with FAB-M4 type (acute myelomonocytic) leukemia. Subsequent Western blot analysis of the cell lysates showed that ATRA induction of FR- expression occurred in all of those samples (Figure 2). Furthermore, the increase in FR- expression could be observed as early as 6 hours after the introduction of ATRA (Figure 2A) and could persist up to 5 days of treatment (Figure 2D). These results extend the observed ATRA induction of FR- in the KG-1 cell line to primary cultures of leukemic cells derived from AML patients. View larger version (28K): [in this window] [in a new window]   Figure 2. ATRA induction of FR- in AML blasts from patient marrow. Cells (1 × 106) were cultured and treated with or without ATRA (1 µmol/L) for 6 hours (panels A and B), 24 hours (panel C), or 5 days (panel D). The samples were obtained from separate patients with FAB-M2 (panels A and C) or FAB-M4 (panels B and D) type AML. Cell lysates were then examined by Western blot with the use of rabbit anti-FR- and AP-conjugated secondary antibody. Effect of ATRA on FR- gene transcription The induction of FR- expression by ATRA in KG-1 cells was accompanied by a specific increase in the FR-, but not FR-, transcript observed in Northern blots (Figure 3A). From nuclear run-on experiments, ATRA increased the transcription rate of the FR- gene in KG-1 cells (Figure 3B). Under similar conditions, neither the mRNA level nor the transcription rate was altered for a control housekeeping gene, the -actin gene (Figure 3). It appears, therefore, that the induction of FR- by ATRA in KG-1 cells may be accounted for, at least in part, by direct or indirect modulation of the FR- gene by ATRA. View larger version (19K): [in this window] [in a new window]   Figure 3. Effect of ATRA on the expression of the FR- transcript. (A) KG-1 cells were treated with ATRA (1 µmol/L), PMA (0.05 µmol/L), or the vehicle alone for 5 days. The total RNA was purified and probed on a Northern blot with cDNA for FR-, FR-, or -actin. (B) KG-1 cells were treated with ATRA (1 µmol/L) for 6 hours. Nuclei were isolated and nuclear run-on reactions carried out as described in "Materials and methods." Labeled RNA isolated from each reaction was used to probe immobilized cDNA for FR- or -actin as described in "Materials and methods." Modulation of FR- expression in KG-1 cells by retinoid analogues Retinoid agonists and antagonists with different specificities for nuclear receptors were tested in KG-1 cells to determine the type(s) of nuclear receptors for retinoids that may mediate ATRA induction of FR-. The retinoid agonists 9-cis RA (pan-RAR, pan-retinoid X receptors [pan-RXR]), TTNPB (pan-RAR), CD336 (RAR), LG101093 (RAR and RAR), and CD2781 (RAR) induced FR- expression, albeit to a lesser extent than ATRA (pan-RAR), whereas CD417 (RAR), CD2314 (RAR), and LG100364 (pan-RXR) had no detectable effect on the level of FR- (Figure 4; Table 3). Among the retinoid antagonists tested, LG100629 (RAR), CD2503 (RAR), and CD2665 (RAR/RAR) counteracted retinoid-agonist-induced FR- expression (Figure 4; Table 3). These results indicate that in KG-1 cells, up-regulation of FR- by retinoids may be mediated by the nuclear receptors, RAR, and/or RAR but not by RAR or by RXRs. View larger version (30K): [in this window] [in a new window]   Figure 4. Effects of various retinoid compounds on FR- expression in KG-1 cells. (A) KG-1 cells were treated with ATRA, 9-cis-RA, LG101093, LG100364, or TTNPB at a concentration of 1 µmol/L or with the vehicle alone for 5 days. Lysates from 1 × 106 cells from each sample were probed on Western blots with rabbit anti-FR- antibody and AP-conjugated secondary antibody. (B) KG-1 cells were treated with different concentrations (107 or 106 mol/L) of CD2665 and CD2503, either alone or in combination with ATRA (1 × 108 mol/L), for 5 days. The cell lysates from each sample were subjected to Western blot analysis as in panel A. (C) KG-1 cells were treated with CD336 or LG101093 at a concentration of 107 mol/L, either alone or in combination with CD2665 or CD2503 (106 mol/L). The cell lysates were analyzed as in panel A. Panels A-C show representative Western blots from at least 3 experiments.                                View this table: [in this window] [in a new window]   Table 3. Nuclear receptor isoform specificities of retinoid analogues and their effects on FR- expression Interestingly, the induction of FR- by the RAR agonist, CD336, was inhibited by the RAR/ antagonist, CD2665, and conversely, the RAR antagonists, CD2503 and LG100629; both counteracted the up-regulation of FR- by the RAR agonist, LG101093 (Figure 4; Table 3). These results show that even though RAR and RAR may independently mediate retinoid induction of FR-, there is an apparent cross-talk between them. Ability of RAR isoforms to mediate ATRA activation of the FR- promoter The inability of RAR agonists to induce FR- expression in KG-1 cells noted above could be attributed to the known lack of RAR in KG-1 cells.24 To test whether RAR can mediate the effect of ATRA on FR- expression, as well as to complement the studies with retinoid compounds described in the previous section, it was of interest to test the effect of ATRA on the activity of the FR- gene promoter and the effect of transiently expressing individual RAR isoforms on the action of ATRA. Owing to the technical difficulty of transfecting KG-1 cells, 293 cells were chosen for these studies. For testing the FR- promoter activity, a luciferase reporter was attached downstream of a 542-base pair genomic fragment of FR- (478nt to +64nt), encompassing the transcription start site at +1nt and the known upstream cis elements required for promoter activity.25 ATRA treatment resulted in an increase in the reporter activity in 293 cells transiently transfected with the promoter construct (Figure 5A). Co-expression of the nuclear receptors, RAR, RAR, and RAR, all resulted in an enhancement of the ATRA effect (Figure 5A). Overexpression of the nuclear receptors also resulted in relatively small but significant increases in the FR- promoter activity, even in the absence of ATRA treatment (Figure 5A); this effect is presumably due to enhancement of the activity of endogenous retinoids in the cells caused by overexpression of RARs. The results suggest that ATRA induction of FR- may be mediated at least in part by activation of the proximal promoter for FR- and that the RAR types , , and  are all capable of mediating this effect. Here, it may be noted that in keeping with the narrow tissue specificity of FR- discussed earlier, the endogenous FR- gene in 293 cells was not expressed under any of the conditions in Figure 5A. View larger version (18K): [in this window] [in a new window]   Figure 5. Effect of ATRA on FR- promoter-luciferase reporter activity in transfected 293 cells. (A) The 293 cells were cotransfected with the FR- promoter linked to a luciferase reporter gene and an expression plasmid for RAR, RAR, or RAR, together with a -galactosidase expression plasmid as described in "Materials and methods." At 8 hours after transfection, ATRA (1 µmol/L) was added, and the cells were cultured for a further 40 hours. Cells were then harvested and lysed with luciferase reporter buffer, and the luciferase activity was determined as described in "Materials and methods." The relative luciferase activity was normalized to -galactosidase activity. (B) Representative clones A and B of recombinant 293 cells stably transfected with the FR- promoter-luciferase reporter construct (described in "Materials and methods") were treated with ATRA (1 µmol/L) for up to 5 days in 6-well plates. The cells were harvested and lysed on days 1, 3, and 5 of the treatment, and the luciferase activity in the lysate was determined as described in "Materials and methods." The relative luciferase activity was normalized to 1 mg of total protein. Response of the FR- promoter to ATRA when stably integrated in the 293-cell genome Following stable integration of the FR- promoter-luciferase reporter fragment into the 293-cell genome, the majority of randomly selected recombinant 293 sublines (21 of 25) showed an induction of the reporter luciferase activity upon ATRA treatment. In representative clones (Figure 5B), ATRA treatment produced up to a 10-fold increase in luciferase activity progressively over a 5-day period, mimicking ATRA induction of FR- in KG-1 cells. This result provides evidence that modulation of the FR- promoter in the chromosome is a major mechanism of FR- induction by ATRA.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Even though FR- is expressed in myeloid leukemia and in several sarcomas, the in vitro expression patterns of the receptor do not generally appear to reflect its in vivo tissue specificity, perhaps owing to events associated with the immortalization of the cell lines in culture9,12 (also, unpublished data, 2000). Among the available myeloid leukemia cell lines tested, KG-1 cells alone expressed FR-. The KG-1 cell line is an AML cell line in which myeloblasts and promyelocytes constitute the predominant population.26 KG-1 cells cannot be induced to produce terminal differentiation by ATRA,27,28 but do differentiate into macrophages in response to phorbol ester.29 Treatment of KG-1 cells with ATRA for a 5-day period resulted in a progressive and dramatic increase in FR- expression; optimal induction of FR- was observed at about 1 µmol/L ATRA, and the effect was reversed upon withdrawal of the reagent. The optimal conditions for FR- induction by ATRA thus occurred under conditions in which myeloid leukemia cells that are therapeutically responsive to ATRA would show growth inhibition and terminal differentiation. The identity of the ATRA-induced protein as cell-surface-associated FR- was established from its reactivity with an antibody specific for this FR isoform,12 its apparent molecular weight of approximately 36 000, and its release by treatment of intact cells with PI-PLC. In contrast to the control HL60 cells, the induction of FR- in KG-1 cells was not associated with significant inhibition of the cell growth in suspension culture and terminal differentiation into either granulocytes or monocytes; the KG-1 cells, however, retained their ability to differentiate into monocytes in response to treatment with phorbol ester. The induction of FR- in KG-1 cells was specific for ATRA since other known differentiating agents (ie, PMA, dexamethasone, vit D3 and TGF-) did not significantly alter FR- expression. The observation of ATRA induction of FR- expression in KG-1 cells was extended to leukemic blasts obtained from AML patient bone marrow aspirates. Of the 4 AML samples tested, 2 were characterized as M2 type AML and 2 as M4 type AML, according to the FAB classification; it may be noted that neither subclass of AML is known to respond favorably to ATRA differentiation therapy. Since FR- is a terminal differentiation marker for neutrophils in normal hematopoiesis, its expression in response to ATRA treatment of leukemic cells in the absence of terminal differentiation may be viewed as a partial differentiation response. Indeed, in the majority of AML cells from different FAB subclasses, ATRA treatment in short-term primary cultures has been reported to alter the expression patterns of myeloid differentiation antigens such as CD33, CD14, and p124 in a manner consistent with changes during normal myelopoiesis.30 The increase in the expression of FR- upon ATRA treatment in KG-1 cells was accompanied by a parallel increase in the FR- mRNA. Furthermore, nuclear run-on data showed that the elevated mRNA level was at least in part caused by an increased rate of transcription of the FR- gene. Retinoid responsive genes that are transcriptionally regulated are known to contain consensus retinoic acid response elements (RAREs) within their promoter sequences.31,32 Inspection of the FR- gene sequence did not reveal consensus RARE sequences, suggesting that activation of the FR- promoter by ATRA may occur by a trans effect. The effects of retinoid agonists and antagonists with different nuclear receptor specificities on FR- expression in KG-1 cells showed that RAR and RAR, but not RXRs, could mediate FR- induction. The inability of RAR-specific retinoids to influence FR- expression may be due to the apparent lack of RAR in KG-1 cells.24 This conclusion is supported by the results in transiently transfected 293 cells in which RARs , , and  were all able to mediate activation of the FR- promoter in response to ATRA. Even though the endogenous FR- gene in 293 cells is inactive, in stable recombinant 293-cell sublines expressing a reporter luciferase under the influence of the FR- promoter, ATRA strikingly stimulated the reporter expression, demonstrating transcriptional control of the FR- gene by ATRA in the chromosomal context. Thus far, our results using established cell lines of diverse cell type and leukemic blasts indicate that up-regulation of the endogenous FR- gene by ATRA does not occur in cells in which the gene is not expressed, presumably because ATRA cannot overcome the repressive mechanisms that ensure tissue specificity of FR-. FR- was down-regulated by ATRA in a squamous cell carcinoma cell line33 and up-regulated in mouse embryonic stem cells,34 but FR- was not expressed in those cells. The effect of ATRA in promoting differentiation is mediated primarily by the nuclear receptor isoform RAR, which is also linked to the molecular mechanism of leukemogenesis in APL.19,35,36 In KG-1 cells, there was apparent cross-talk between retinoid agonists and antagonists with different RAR isoform specificities with respect to FR- regulation, suggesting that a common downstream target for the receptors mediates trans activation of the FR- gene. The pathway for FR- induction by ATRA is therefore clearly distinct from that leading to terminal differentiation, which is mediated principally by RAR. The refractoriness of ATRA-resistant APL cells, as well as other malignant cell types, to retinoid differentiation therapy has been attributed to various resistance mechanisms. Reduced intracellular availability of retinoids due to either accelerated in vivo clearance37 or increased levels of cellular retinoic acid binding protein38-40 may occur in the resistant cells. More recent studies have implicated alterations in the level of RAR or PML/RAR41-43 and mutations in PML/RAR44-48 as a major cause of in vitro as well as clinical resistance to ATRA. As discussed above, retinoids may use any of the 3 RAR isoforms to induce FR- expression, and therefore retinoid regulation of FR- would be unaffected by differences in RAR levels or by mutations that decrease the affinity of ATRA for RAR. Recent studies with variant APL-derived cell lines, as well as primary cultures of non-APL myeloid leukemia cells, have characterized the cell growth inhibition, terminal differentiation, and apoptosis resulting from ATRA treatment of APL as independent events.49-51 The therapeutic action of ATRA in APL is, therefore, the net result of its pleiotropic actions in the cell. It follows that a block in any one critical pathway of ATRA action leading to ATRA resistance should not affect its ability to modulate a variety of genes. The studies described in this article would predict that ATRA could up-regulate FR- in various retinoid-resistant myeloid leukemias as well as in APL cells harboring minimal residual disease following ATRA therapy. The elevated FR- may serve as an effective target for therapy following retinoid treatment.     Acknowledgments We thank Dr Elizabeth Allegreto (Ligand Pharmaceuticals Inc, San Diego, CA) and Dr Uwe Reichert (Galderma Research and Development, Valbonne, France) for sharing various retinoid compounds; Dr Pierre Chambon (Institute de Genetique et de Biologie Moleculaire et Cellulaire, Cude Strasbourg, France) for providing the RAR cDNAs; Jenny Zak and Anna Chlebowski for typing the manuscript; and Thomas Sawyer for his invaluable help in the use of the flow cytometer.     Footnotes Submitted March 27, 2000; accepted July 6, 2000. Supported by National Institutes of Health R01 grants CA80183 and CA70873 to M.R. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Manohar Ratnam, Medical College of Ohio, Department of Biochemistry and Molecular Biology, 3035 Arlington Ave, Toledo, OH 43614-5804; e-mail: mratnam{at}mco.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Lacey SW, Sanders JM, Rothberg KG, Anderson RG, Kamen BA. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J Clin Invest. 1989;84:715-720. 2. Ratnam M, Marquardt H, Duhring JL, Freisheim JH. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry. 1989;28:8249-8254[Medline] [Order article via Infotrieve]. 3. Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type  is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995;34:5660-5665[Medline] [Order article via Infotrieve]. 4. Shen F, Wang H, Zheng X, Ratnam M. Expression levels of functional folate receptors- and - are related to the number of N-glycosylated sites. Biochem J. 1997;327:759-764. 5. Yan W, Ratnam M. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry. 1995;34:14594-14600[Medline] [Order article via Infotrieve]. 6. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci. 1993;106:423-430[Abstract]. 7. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88:5572-5576[Abstract/Free Full Text]. 8. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissue. Cancer Res. 1992;52:3396-3401[Abstract/Free Full Text]. 9. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer. 1994;73:2432-2443[Medline] [Order article via Infotrieve]. 10. Wu M, Gunning W, Ratnam M. Expression of folate receptor type  in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999;8:775-782[Abstract/Free Full Text]. 11. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst. 1998;15:587-627[Medline] [Order article via Infotrieve]. 12. Ross JF, Wang H, Behm FG, et al. Folate receptor type  is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85:348-357[Medline] [Order article via Infotrieve]. 13. Nakashima-Matsushita N, Homma T, Yu S, et al. Selective expression of folate receptor  and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:1609-1616[Medline] [Order article via Infotrieve]. 14. Fischer CD, da Costa M, Rothenberg SP. The heterogeneity and properties of folate binding proteins from chronic myelogenous leukemia cells. Blood. 1975;46:855-867[Abstract/Free Full Text]. 15. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type  in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994;33:1209-1215[Medline] [Order article via Infotrieve]. 16. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the -isoform of the folate receptor on CD34+ cells. Blood. 1999;93:3940-3948[Abstract/Free Full Text]. 17. Piedrahita JA, Oetama B, Bennett GD, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet. 1999;23:228-232[Medline] [Order article via Infotrieve]. 18. Tallman MS. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia. 1998;12(suppl 1):S37-S40. 19. Coco FL, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia. 1998;12:1866-1880[Medline] [Order article via Infotrieve]. 20. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol. 1992;44:1898-1901[Medline] [Order article via Infotrieve]. 21. Kizaki M, Matsushita H, Takayama N, et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood. 1996;88:1824-1833[Abstract/Free Full Text]. 22. Garber M, Panchanathan S, Fan RS, Johnson DL. The phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate, induces specific transcription by RNA polymerase III in Drosophila Schneider cells. J Biol Chem. 1991;266:20598-20601[Abstract/Free Full Text]. 23. Wang H, Ross JF, Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type /'. Nucleic Acids Res. 1998;26:2132-2142[Abstract/Free Full Text]. 24. Largman C, Detmer K, Corral JC, Hack FM, Lawrence HJ. Expression of retinoic acid receptor alpha mRNA in human leukemia cells. Blood. 1989;74:99-102[Abstract/Free Full Text]. 25. Sadasivan E, Cedeno MM, Rothenberg SP. Characterization of the gene encoding a folate-binding protein expressed in human placenta. J Biol Chem. 1994;269:4725-4735[Abstract/Free Full Text]. 26. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood. 1980;56:344-350[Abstract/Free Full Text]. 27. Douer D, Koeffler HP. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res. 1982;138:193-198[Medline] [Order article via Infotrieve]. 28. Ferrero D, Pessano S, Pagliardi GL, Rovera G. Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. Blood. 1983;61:171-179[Abstract/Free Full Text]. 29. Koeffler HP, Bar-Eli M, Territo MC. Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation. Cancer Res. 1981;41:919-926[Abstract/Free Full Text]. 30. Howell AL, Stukel TA, Bloomfield CD, Davey FR, Ball ED. Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia. Blood. 1990;75:721-729[Abstract/Free Full Text]. 31. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell. 1991;65:1255-1266[Medline] [Order article via Infotrieve]. 32. Mangelsdorf DJ, Umesono K, Kllewer SA, Borgmeyer U, Ong ES, Evans RM. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell. 1991;66:555-561[Medline] [Order article via Infotrieve]. 33. Orr RB, Kreisler AR, Kamen BA. Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers. J Natl Cancer Inst. 1995;87:299-303[Abstract/Free Full Text]. 34. Bolton JA, Wood SA, Kennedy D, Don RH, Mattick JS. Retinoic acid-dependent upregulation of mouse folate receptor- expression in embryonic stem cells, and conservation of alternative splicing patterns. Gene. 1999;230:215-224[Medline] [Order article via Infotrieve]. 35. Melnick A, Licht JD. Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215[Free Full Text]. 36. Gaboli M, Gandini D, Delva L, Wang Z-G, Pandolfi PD. Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. Leuk Lymphoma. 1998;30:11-22[Medline] [Order article via Infotrieve]. 37. Muindi J, Frankel SR, Miller WH Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992;79:299-303[Abstract/Free Full Text]. 38. Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood. 1993;82:2175-2181[Abstract/Free Full Text]. 39. Cornic M, Delva L, Castaigne S, et al. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia. 1994;8(suppl 2):S16-S19. 40. Warrell R Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood. 1993;82:1949-1953[Free Full Text]. 41. Wu Q, Dawson MI, Zheng Y, et al. Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol. 1997;17:6598-6608[Abstract]. 42. Nason-Burchenal K, Allopenna J, Bègue A, Stéhelin D, Dmitrovsky E, Martin P. Targeting of PML/RAR is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood. 1998;92:1758-1767[Abstract/Free Full Text]. 43. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG. Constitutive degradation of PML/RAR through the proteasome pathway mediates retinoic acid resistance. Blood. 1999;93:1477-1481[Abstract/Free Full Text]. 44. Dermine S, Grignani F, Clerici M, et al. The occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RAR alpha protein. Blood. 1993;82:1573-1577[Abstract/Free Full Text]. 45. Rosenauer A, Raelson JV, Nervi C, Eydoux P, Deblasio A, Miller WH Jr. Alteration in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood. 1996;88:2671-2682[Abstract/Free Full Text]. 46. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR mutation. Blood. 1997;89:4282-4289[Abstract/Free Full Text]. 47. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811-814[Medline] [Order article via Infotrieve]. 48. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 1998;92:374-382[Abstract/Free Full Text]. 49. Sakashita A, Kizaki M, Pakkala S, et al. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood. 1993;81:1009-1016[Abstract/Free Full Text]. 50. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994;372:107-111[Medline] [Order article via Infotrieve]. 51. Grillier I, Umiel T, Elstner E, Collins SJ, Koeffler HP. Alterations of differentiation, clonal proliferation, cell cycle progression and bcl-2 expression in RAR-altered sublines of HL-60. Leukemia. 1997;11:393-400[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Qi and M. Ratnam Synergistic Induction of Folate Receptor {beta} by All-Trans Retinoic Acid and Histone Deacetylase Inhibitors in Acute Myelogenous Leukemia Cells: Mechanism and Utility in Enhancing Selective Growth Inhibition by Antifolates Cancer Res., June 1, 2006; 66(11): 5875 - 5882. [Abstract] [Full Text] [PDF] T. Tran, A. Shatnawi, X. Zheng, K. M.M. Kelley, and M. Ratnam Enhancement of Folate Receptor {alpha} Expression in Tumor Cells Through the Glucocorticoid Receptor: A Promising Means to Improved Tumor Detection and Targeting Cancer Res., May 15, 2005; 65(10): 4431 - 4441. [Abstract] [Full Text] [PDF] K. M. M. Kelley, B. G. Rowan, and M. Ratnam Modulation of the Folate Receptor {alpha} Gene by the Estrogen Receptor: Mechanism and Implications in Tumor Targeting Cancer Res., June 1, 2003; 63(11): 2820 - 2828. [Abstract] [Full Text] [PDF] H. Hao, H. Qi, and M. Ratnam Modulation of the folate receptor type {beta} gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites Blood, June 1, 2003; 101(11): 4551 - 4560. [Abstract] [Full Text] [PDF] X. Zheng, K. Kelley, H. Elnakat, W. Yan, T. Dorn, and M. Ratnam mRNA Instability in the Nucleus Due to a Novel Open Reading Frame Element Is a Major Determinant of the Narrow Tissue Specificity of Folate Receptor {alpha} Mol. Cell. Biol., March 15, 2003; 23(6): 2202 - 2212. [Abstract] [Full Text] [PDF] X. Q. Pan, X. Zheng, G. Shi, H. Wang, M. Ratnam, and R. J. Lee Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta -targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid Blood, June 28, 2002; 100(2): 594 - 602. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Ratnam, M. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Ratnam, M. Related Collections Neoplasia Immunotherapy Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020